Slow-Release Oral Morphine for the Treatment of Opioid Use Disorder — pRESTO  

Opioid-Related Disorders Clinical Trial

Official title: Repurposing Slow-Release Oral Morphine as a New Oral Alternative for the Treatment of Opioid Use Disorder

Status Terminated

Clinical Trial Summary

This is a non-inferiority randomized clinical trial that will compare slow release oral morphine vs methadone as a second line oral treatment for opioid use disorder.

Clinical Trial Description

Slow-release oral morphine (SROM) has emerged as a promising yet understudied form of oral treatment for opioid use disorder (OUD), with preliminary studies suggesting similar efficacy rates as methadone with respect to promoting abstinence, and with better improvements in a number of patient-reported outcomes, including tolerability, treatment satisfaction, mental symptoms, and craving. The proposed study is an open-label, non-inferiority, randomized controlled trial evaluating the relative effectiveness, safety and acceptability of SROM vs. methadone for the treatment of OUD in outpatient clinical settings. Participants will be randomized 1:1 to SROM or methadone for 24 weeks. Data linkages performed three years after randomization will evaluate long term health outcomes. This study aims to provide evidence to optimize care for individuals with OUD, and potentially increase access to additional form of evidence-based oral treatment. ;

Related Conditions & MeSH terms

• Disease
• Fentanyl
• Methadone
• Morphine
• Opiate Substitution Treatment
• Opioid-Related Disorders

• NCT number: NCT03948464
• Study type: Interventional
• Source: BC Centre on Substance Use
• Status: Terminated
• Phase: Phase 3
• Start date: December 6, 2019
• Completion date: June 1, 2020